Analytical Data
-
Gene name
Integrin alpha 6 beta 1
- Application
-
Alternative Names
CD49f; CD49-F; ITG-A6; ITGA6B; VLA-6; CD49 antigen-like family member F; Processed integrin alpha-6
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P23229
-
Expression Region
Phe24~Asn478
-
Molecular Weight
56kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Integrin alpha 6 beta 1 is a significant cell adhesion receptor that plays a crucial role in various biological processes, including cellular migration, differentiation, and signaling. This heterodimeric protein primarily interacts with extracellular matrix components, such as laminin, influencing tissue architecture and homeostasis. Research on integrin alpha 6 beta 1 has gained momentum due to its implications in cancer metastasis, wound healing, and tissue repair, where abnormal expression or function can lead to pathological conditions. Notably, integrins serve as potential therapeutic targets; thus, understanding the molecular mechanisms of integrin alpha 6 beta 1 can facilitate the development of novel interventions for diseases associated with its dysregulation. Recent advances in recombinant protein technology have allowed for the production and purification of functional integrin alpha 6 beta 1, enabling researchers to explore its structure, binding properties, and role in cell signaling pathways. Studies utilizing recombinant integrin have elucidated its involvement in tumor progression and immune responses, highlighting the protein's potential as a biomarker and therapeutic target. This growing body of research underscores the importance of integrin alpha 6 beta 1 in both basic biology and clinical applications, paving the way for new strategies to manipulate its activity in disease contexts.
